KURANasdaqPharmaceutical PreparationsFiscal year ends December 31

Kura Oncology, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$9.36+0.28 (+3.08%)

Close on Oct 19, 2026

Market cap: $831.68M
P/E (TTM): –
Dividend yield: –

Kura Oncology, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31	FY 2007 2007-12-31
Revenue	67	54	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Research & Development	251	170	115	93	85	60	48	47	26	–	–	–	–	–	–	–	–	–	–
Selling, General & Admin	120	77	51	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
General & Administrative	–	77	51	47	47	32	20	16	9.65	–	–	0.02	0.02	0.02	0.02	0.02	–	–	–
Advertising Expenses	2.80	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Operating Expenses	371	247	166	140	131	92	67	63	36	28	24	–	–	–	–	–	–	–	–
Operating Income	-304	-193	-166	-140	–	–	–	–	–	–	–	-0.02	-0.02	-0.02	-0.02	-0.02	–	–	–
Interest Expense	1.51	1.62	1.55	0.23	0.41	0.58	0.58	0.97	0.89	0.58	0.04	0.01	0.01	0.00	0.00	0.00	–	–	–
Interest & Investment Income	–	–	–	–	–	–	–	–	0.75	0.50	0.13	–	–	–	–	–	–	–	–
Other Non-Operating Income	25	21	13	4.03	0.79	2.27	4.34	2.44	0.64	0.81	1.24	–	–	–	–	–	–	–	–
Asset Impairment Charges	0	0	0	0	0	0	0	0	0	0	0	–	–	–	–	–	–	–	–
Pretax Income	-278	-172	-153	-136	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Income Tax Expense	0.30	2.02	0	0	0	0	0	0	0	0	0	–	–	–	–	–	–	–	–
Net Income	-279	-174	-153	-136	-130	-90	-63	-60	-35	-28	-23	-0.03	-0.03	-0.03	-0.03	-0.02	-0.02	-0.03	-0.01
EPS (Basic)(per share)	-3.18	-2.02	-2.08	-2.03	-1.97	-1.69	-1.51	-1.72	-1.52	-1.47	-2.28	-0.01	-0.01	-0.01	-0.01	0.00	–	–	–
EPS (Diluted)(per share)	-3.18	-2.02	-2.08	-2.03	-1.97	-1.69	-1.51	-1.72	-1.52	-1.47	-2.28	-0.01	-0.01	-0.01	-0.01	0.00	–	–	–
Shares Outstanding (Basic, Weighted)(shares)	88	86	73	67	66	53	42	35	23	19	9.93	5.00	5.00	5.00	5.00	–	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	88	86	73	67	66	53	42	35	23	19	9.93	5.00	5.00	5.00	5.00	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -411.9%
Net margin: -384.3%
Return on equity, FY2025: -94.8%

Financial strength

Current ratio: 4.73
Debt to equity: 0.20
Debt to assets: 1.7%
Cash to current liabilities: 59.4%

Valuation

P/E ratio: –
Price to sales: 10.77
Price to book: 17.17
Dividend yield: –